Interim report 1 January – 30 June 2024

Good growth in both Business Areas and continued profitability improvement

		The companies within AddLife showed strong performance development during the quarter. In Labtech, sales growth recovered as expected and margins remained stable. Sales growth in Medtech was good and margins improved partly driven by restructuring efforts that are now yielding clear results. Cash flow improved significantly and after the end of the quarter, an acquisition was made in line with our updated long-term strategy.
		Fredrik Dalborg, President and CEO

1 APRIL – 30 JUNE 2024 (3 MONTHS)

• Net sales increased by 8% to SEK 2,554m (2,365). The organic growth, excluding exchange rate changes, was 7%. 
• EBITA increased by 21% to SEK 299m (247), corresponding to an EBITA-margin of 11.7% (10.4). 
• Profit after tax for the quarter increased by 116% to SEK 72m (33).
• Earnings per share amounted to SEK 0.60 (0.27).
• Cash flow from operating activities amounted to SEK 195m (82).

1 JANUARY – 30 JUNE 2024 (6 MONTHS)

• Net sales increased by 6% to SEK 5,124m (4,822). The organic growth, excluding exchange rate changes, was 5%. 
• EBITA decreased by 4% to SEK 590m (613), corresponding to an EBITA-margin of 11.5% (12.7). EBITA includes reversed contingent considerations of SEK 7m (83). Adjusted for this EBITA increased by 10% and the EBITA margin amounted to 11.4% (11.0).
• Profit after tax for the period amounted to SEK 135m (207).
• Earnings per share amounted to SEK 1.11 (1.70). Earnings per share for the last 12 months amounted to SEK 0.97 (3.19)
• Cash flow from operating activities amounted to SEK 292m (187).

• The equity ratio was 39% (39).
• Return on working capital (P/WC) amounted to 48% (50).